“Tonight we hosted a dinner with VYGR just after the announcement that SNY did not.”,” Cowen and Company’s analyst wrote.
Several other analysts have also recently weighed in on the company. Wedbush reaffirmed a positive rating and set a $31.00 price objective (down from $36.00) on shares of Voyager Therapeutics in a research report on Tuesday. Robert W. Baird assumed coverage on Voyager Therapeutics in a research report on Monday. They set an outperform rating and a $31.00 price objective on the stock. Canaccord Genuity assumed coverage on shares of Voyager Therapeutics in a report on Friday, October 27th. They set a buy rating and a $35.00 target price for the company. Stifel Nicolaus reiterated a buy rating and set a $31.00 target price (up from $20.00) on shares of Voyager Therapeutics in a report on Monday, October 23rd. Finally, Zacks Investment Research lowered shares of Voyager Therapeutics from a hold rating to a sell rating in a report on Tuesday, October 17th. Two analysts have rated the stock with a sell rating, two have assigned a hold rating and ten have given a buy rating to the company’s stock. Voyager Therapeutics currently has an average rating of Buy and a consensus price target of $28.89.
Voyager Therapeutics (NASDAQ:VYGR) traded down 2.47% on Tuesday, reaching $20.54. The company had a trading volume of 327,047 shares. The firm’s market capitalization is $552.59 million. The company’s 50 day moving average is $20.15 and its 200-day moving average is $12.34. Voyager Therapeutics has a one year low of $8.10 and a one year high of $25.99.
Voyager Therapeutics (NASDAQ:VYGR) last posted its quarterly earnings data on Tuesday, August 8th. The company reported ($0.73) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.62) by ($0.11). The firm had revenue of $1.18 million for the quarter, compared to the consensus estimate of $3.27 million. Voyager Therapeutics had a negative net margin of 712.22% and a negative return on equity of 46.15%. On average, equities research analysts expect that Voyager Therapeutics will post ($2.89) earnings per share for the current fiscal year.
TRADEMARK VIOLATION WARNING: “Voyager Therapeutics, Inc. (VYGR) Given “Buy” Rating at Cowen and Company” was first posted by Sports Perspectives and is the sole property of of Sports Perspectives. If you are viewing this piece of content on another domain, it was copied illegally and reposted in violation of United States and international trademark & copyright laws. The correct version of this piece of content can be accessed at https://sportsperspectives.com/2017/11/01/voyager-therapeutics-inc-vygr-given-buy-rating-at-cowen-and-company.html.
In other news, insider Bernard Ravina sold 10,980 shares of Voyager Therapeutics stock in a transaction that occurred on Tuesday, October 10th. The shares were sold at an average price of $20.33, for a total transaction of $223,223.40. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Insiders have sold 32,940 shares of company stock valued at $490,092 over the last quarter. Company insiders own 8.00% of the company’s stock.
Hedge funds have recently added to or reduced their stakes in the company. Russell Investments Group Ltd. lifted its holdings in shares of Voyager Therapeutics by 57.7% during the second quarter. Russell Investments Group Ltd. now owns 11,864 shares of the company’s stock valued at $106,000 after purchasing an additional 4,343 shares during the last quarter. Hershey Trust Co. raised its holdings in Voyager Therapeutics by 163.0% in the 2nd quarter. Hershey Trust Co. now owns 14,394 shares of the company’s stock worth $129,000 after acquiring an additional 8,921 shares during the last quarter. Oppenheimer & Co. Inc. purchased a new position in Voyager Therapeutics in the 2nd quarter worth approximately $143,000. Rhumbline Advisers raised its holdings in Voyager Therapeutics by 34.7% in the 2nd quarter. Rhumbline Advisers now owns 16,091 shares of the company’s stock worth $144,000 after acquiring an additional 4,144 shares during the last quarter. Finally, Goldman Sachs Group Inc. raised its holdings in Voyager Therapeutics by 8.9% in the 2nd quarter. Goldman Sachs Group Inc. now owns 17,048 shares of the company’s stock worth $153,000 after acquiring an additional 1,399 shares during the last quarter. Hedge funds and other institutional investors own 40.72% of the company’s stock.
Voyager Therapeutics Company Profile
Voyager Therapeutics, Inc is a clinical-stage gene therapy company. The Company focuses on developing treatments for patients suffering from severe diseases of the central nervous system (CNS). The Company’s pipeline consists of programs for CNS indications, including advanced Parkinson’s disease; a monogenic form of amyotrophic lateral sclerosis (ALS); Huntington’s disease; Friedreich’s ataxia; frontotemporal dementia/Alzheimer’s disease, and severe chronic pain.
Receive News & Ratings for Voyager Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Voyager Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.